American Equity Investment Life Holding Company (AEL) Analysts See $0.67 EPS; Halo Technology Holdings (HALO) Sentiment Is 1.26

February 6, 2018 - By Henry Gaston

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company has market cap of $2.51 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. It currently has negative earnings. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Analysts expect American Equity Investment Life Holding Company (NYSE:AEL) to report $0.67 EPS on February, 14.They anticipate $0.04 EPS change or 6.35% from last quarter’s $0.63 EPS. AEL’s profit would be $59.71 million giving it 11.52 P/E if the $0.67 EPS is correct. After having $0.96 EPS previously, American Equity Investment Life Holding Company’s analysts see -30.21% EPS growth. The stock decreased 6.62% or $2.19 during the last trading session, reaching $30.88. About 701,270 shares traded or 1.68% up from the average. American Equity Investment Life Holding Company (NYSE:AEL) has risen 64.86% since February 6, 2017 and is uptrending. It has outperformed by 48.16% the S&P500.

Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on February, 27. They expect $0.67 earnings per share, up 419.05% or $0.88 from last year’s $-0.21 per share. HALO’s profit will be $94.50M for 6.63 P/E if the $0.67 EPS becomes a reality. After $0.02 actual earnings per share reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 3,250.00% EPS growth.

Third Security Llc holds 19.28% of its portfolio in Halozyme Therapeutics, Inc. for 17.59 million shares. Senzar Asset Management Llc owns 3.83 million shares or 16.24% of their US portfolio. Moreover, Bb Biotech Ag has 4.15% invested in the company for 8.63 million shares. The Minnesota-based First Light Asset Management Llc has invested 2.45% in the stock. Snyder Capital Management L P, a California-based fund reported 2.47 million shares.

The stock decreased 3.32% or $0.61 during the last trading session, reaching $17.76. About 1.10 million shares traded. Halozyme Therapeutics, Inc. (HALO) has risen 44.89% since February 6, 2017 and is uptrending. It has outperformed by 28.19% the S&P500.

Investors sentiment decreased to 1.26 in Q3 2017. Its down 0.01, from 1.27 in 2017Q2. It turned negative, as 21 investors sold American Equity Investment Life Holding Company shares while 65 reduced holdings. 36 funds opened positions while 72 raised stakes. 81.49 million shares or 0.46% more from 81.11 million shares in 2017Q2 were reported. Us Natl Bank De holds 0.01% or 56,342 shares in its portfolio. Tci Wealth Advsrs reported 499 shares stake. Moreover, Victory Capital Management Incorporated has 0.08% invested in American Equity Investment Life Holding Company (NYSE:AEL). Apollo Limited Partnership invested in 1.43% or 3.27M shares. Royal Bancorp Of Canada stated it has 0% in American Equity Investment Life Holding Company (NYSE:AEL). Lomas Capital Mgmt has invested 0.33% of its portfolio in American Equity Investment Life Holding Company (NYSE:AEL). 598,758 are held by Kennedy Capital Mgmt Inc. Origin Asset Mngmt Llp owns 11,020 shares. Lazard Asset Lc has 0% invested in American Equity Investment Life Holding Company (NYSE:AEL). 95,741 were reported by Convergence Llc. Citigroup has 0% invested in American Equity Investment Life Holding Company (NYSE:AEL) for 1,321 shares. State Board Of Administration Of Florida Retirement Sys owns 65,538 shares or 0.01% of their US portfolio. Pnc Fincl Svcs Gru Inc reported 0% stake. Earnest Ptnrs Limited Liability Company accumulated 2.71 million shares. Goldman Sachs Inc has invested 0.01% of its portfolio in American Equity Investment Life Holding Company (NYSE:AEL).

American Equity Investment Life Holding Company, through its subsidiaries, develops and sells fixed index and fixed rate annuity products in the United States. The company has market cap of $2.75 billion. It issues fixed index annuities and fixed rate annuities, as well as single premium immediate annuities. It has a 10.81 P/E ratio. The firm also offers life insurance products comprising traditional ordinary and term, universal life, and other interest-sensitive life insurance products.

Among 9 analysts covering American Equity Investment Life (NYSE:AEL), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. American Equity Investment Life had 35 analyst reports since August 10, 2015 according to SRatingsIntel. The stock has “Mkt Perform” rating by Keefe Bruyette & Woods on Wednesday, April 26. As per Friday, January 8, the company rating was initiated by JP Morgan. The rating was downgraded by Evercore to “In-Line” on Tuesday, July 25. On Monday, August 10 the stock rating was maintained by FBR Capital with “Outperform”. The firm has “Outperform” rating given on Thursday, February 11 by RBC Capital Markets. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, August 4. The stock of American Equity Investment Life Holding Company (NYSE:AEL) earned “Buy” rating by RBC Capital Markets on Tuesday, September 5. FBR Capital maintained American Equity Investment Life Holding Company (NYSE:AEL) on Monday, November 28 with “Outperform” rating. FBR Capital maintained it with “Outperform” rating and $30 target in Monday, February 13 report. The stock has “Market Perform” rating by Raymond James on Monday, August 10.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Henry Gaston

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: